Dibutyryl-cGMP (sodium)

Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analogue. Dibutyryl-cGMP sodium preferentially activates cGMP-dependent protein kinase (PKG) . Dibutyryl-cGMP sodium inhibits the release of [3H]-arachidonic acid from γ thrombin-stimulated human platelets. Dibutyryl-cGMP sodium induces peripheral antinociception via activation of ATP-sensitive K+ channels[1][2][3].

Product Specifications

CAS Number

[51116-00-8]

Product Name Alternative

Bt2cGMP (sodium)

UNSPSC

12352005

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/dibutyryl-cgmp-sodium.html

Purity

99.66

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

CCCC(NC1=NC2=C(C(N1)=O)N=CN2[C@H]3[C@@H]([C@H]4[C@H](O3)COP(O4)(O[Na])=O)OC(CCC)=O)=O

Molecular Formula

C18H23N5NaO9P

Molecular Weight

507.37

References & Citations

[1]Borán MS, et al. The cyclic GMP-protein kinase G pathway regulates cytoskeleton dynamics and motility in astrocytes. J Neurochem. 2007 Jul;102 (1) :216-30.|[2]Sane DC, et al. Cyclic GMP analogs inhibit gamma thrombin-induced arachidonic acid release in human platelets. Biochem Biophys Res Commun. 1989 Dec 15;165 (2) :708-14.|[3]Soares AC, et al. Dibutyryl-cyclic GMP induces peripheral antinociception via activation of ATP-sensitive K (+) channels in the rat PGE2-induced hyperalgesic paw. Br J Pharmacol. 2001 Sep;134 (1) :127-31.